Rasagiline Mesylate Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 1 mg
Reference Brands: Azilect (USA),
Category:
Neurology
Rasagiline mesylate is available in Tablets
and strengths such as 1 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Rasagiline mesylate is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Rasagiline mesylate can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Rasagiline is a selective monoamine oxidase-B (MAO-B) inhibitor widely used in the management of Parkinson’s disease. It is prescribed as monotherapy in the early stages of Parkinson’s disease to help control symptoms such as tremor, rigidity, and slowness of movement, and as an adjunct therapy in more advanced stages alongside levodopa to reduce motor fluctuations and “off” episodes. By inhibiting the breakdown of dopamine in the brain, rasagiline increases and prolongs dopamine activity, which is essential for improving motor control in patients with Parkinson’s disease.
In addition to its benefits on motor symptoms, rasagiline has demonstrated effectiveness in addressing certain non-motor symptoms of Parkinson’s disease, including fatigue, which can significantly impact quality of life. Its once-daily oral dosing and favorable tolerability profile make it a convenient and well-accepted option for long-term therapy. Clinical studies such as the TEMPO and ADAGIO trials explored the potential disease-modifying effects of rasagiline; however, regulatory authorities concluded that available evidence supports its role as a symptomatic treatment rather than a proven neuroprotective therapy. Overall, rasagiline remains an important and established treatment option in both early and advanced Parkinson’s disease management.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing